Comparative Pharmacology
Head-to-head clinical analysis: CODIMAL L A 12 versus COLD CAPSULE IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CODIMAL L A 12 versus COLD CAPSULE IV.
CODIMAL-L.A. 12 vs COLD CAPSULE IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codimal-L.A. 12 contains chlorpheniramine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors. Chlorpheniramine competitively blocks histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine causes vasoconstriction via alpha-1 adrenergic receptor activation, leading to nasal decongestion.
Combination of antihistamine (chlorpheniramine) blocking H1 receptors, nasal decongestant (phenylephrine) causing vasoconstriction, and analgesic/antipyretic (acetaminophen) inhibiting COX enzymes in CNS.
One tablet orally every 12 hours. Each tablet contains 25 mg phenylpropanolamine HCl and 4 mg chlorpheniramine maleate.
1-2 capsules orally every 4-6 hours as needed for symptoms; maximum 12 capsules per day.
None Documented
None Documented
12 hours (terminal); supports once-daily dosing, steady-state in 2-3 days.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pseudoephedrine: 5-8 hours (alkaline urine increases half-life). Dextromethorphan: 3-5 hours (CYP2D6 poor metabolizers: up to 20 hours).
Renal: 90% (unchanged drug). Biliary/fecal: <10%.
Renal elimination of acetaminophen metabolites (primarily glucuronide and sulfate conjugates) accounts for ~85-90% of the dose; unchanged drug <5%. Pseudoephedrine and dextromethorphan are primarily excreted renally (70-90% and 50-80% respectively, with some biliary/fecal).
Category C
Category C
Cold & Cough Combination
Cold & Cough Combination